Twentyeight Health vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Twentyeight Health provides affordable telehealth and mail-order pharmacy for contraception, STI testing, and reproductive health to underserved and low-income women.
About
Twentyeight Health is a reproductive health telehealth company founded in 2019 that focuses specifically on expanding access to contraception and reproductive healthcare for underserved women, including those on Medicaid, without insurance, or in rural areas. The platform provides online consultations with licensed providers for birth control prescriptions, STI testing kits by mail, emergency contraception, and general reproductive health questions at accessible price points with Medicaid acceptance. Twentyeight raised $25M and has enrolled hundreds of thousands of patients, with a focus on the communities most affected by reproductive healthcare access gaps. The company differentiates from other telehealth platforms by prioritizing Medicaid acceptance, multilingual care, and a health equity mission rather than serving primarily the commercially insured population. Twentyeight operates in most US states and has built relationships with state health departments and safety-net healthcare organizations. As access to reproductive healthcare has become more constrained in some US states, Twentyeight's telehealth model has become an increasingly critical access point for patients who cannot easily reach in-person reproductive health services.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.